Page 52 - CIBEREHD2016-ENG

LEAD rESEArCHEr
Bruix Tudó, Jordi
Hospital Clínico y Provincial de Barcelona
Villarroel, 170
08036 Barcelona
(+34) 93 227 98 03 [email protected] group Website
GROUP MEMBERS
Staff members: Boix Ferrero, Loreto | Díaz González, Álvaro | Esteva Espinosa, Clara | Iserte Fort, Gemma | Peix Gallofré, Judit | Sapena Masip, Víctor | Torrens Fontanals, Laura
Associated members: Ayuso Colella, María Carmen | Bianchi Cardona, Luis | Bru Saumell, Concepción
| Forner González, Alejandro | Fuster Obregón, Josep | Llovet Bayer, Josep Maria | Reig Monzón, Ma Elisa | Solé Arqués, Manuel | Vilana Puig, Ramón
Main lines of research
This group known as the BCLC group is devoted to clinical and translational research in liver cancer, especially to two major fields: clinical research and molecular profiling. As a referral group it maintains an intense clinical activity that allows running studies including from epidemiology to diagnosis, prognosis and treatment. The creation of a tissue collection and the organization of an International Genomic Consortium with other institutions from abroad (Mount Sinai Medical School in New York, Harvard University, Institute Nationale di Tumori di Milan) has facilitated several investigations to expand the knowledge of the oncogenic mechanisms, the proposal of a molecular classification for liver cancer and the identification of potential novel targets.
The BCLC group has received wide international recognition for its work at all levels. At the clinical level the group established the relevance of hepatitis C virus infection as a risk factor for liver cancer, defined the imaging criteria for imaging diagnosis of liver cancer, defined the role of portal pressure measurement in the selection of candidates for surgery, established the benefits of ablation for early stage cancers
and, more importantly, demonstrated the benefit of chemoembolization and sorafenib through phase 3 randomised trials.
52
PROGRAMMES
P4